Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 28;307(12):1254-6.
doi: 10.1001/jama.2012.358.

Mortality in adults with sickle cell disease and pulmonary hypertension

Alem Mehari  1 , Mark T Gladwin, Xin Tian, Roberto F Machado, Gregory J Kato
Affiliations

Mortality in adults with sickle cell disease and pulmonary hypertension

Alem Mehari et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gladwin reported that grant money was paid to his institution by Bayer Corporation and INO Therapeutics and money was paid by the US government to his institution for patents in which he is the co-inventor and coauthor. No other author reported disclosures.

Figures

Figure
Figure. Kaplan-Meier Estimates of Survival for Patients With Sickle Cell Disease by Pulmonary Hypertension Status
A, The age-adjusted hazard ratio (AHR) was 3.43 (95% CI, 1.02–11.55; P = .047) for the comparison between patients with pulmonary hypertension documented by right heart catheterization (RHC) and those who did not have pulmonary hypertension documented by RHC; 2.14 (95% CI, 1.25–3.67; P = .006) for patients with pulmonary hypertension vs those who did not undergo RHC (uncatheterized); and 0.62 (95% CI, 0.19–2.03; P = .43) for patients without pulmonary hypertension vs those who did not undergo RHC (uncatheterized). B, The HR was 3.35 (95% CI, 1.01–11.31; P = .04) for the comparison between patients with pulmonary hypertension documented by RHC and those who did not have pulmonary hypertension documented by RHC; 1.73 (95% CI, 1.02–2.93; P = .04) for patients with pulmonary hypertension vs those who did not undergo RHC (uncatheterized); and 0.49 (95% CI, 0.15–1.59; P = .23) for patients without pulmonary hypertension vs those who did not undergo RHC (uncatheterized).
See this image and copyright information in PMC

References

    1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886–895. - PubMed
    1. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109–115. - PubMed
    1. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687–692. - PubMed
    1. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44–53. - PubMed
    1. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112–118. - PubMed

Publication types